Join
Live feed
·
PRReleasevia Quantisnow
Viridian Therapeutics Inc. logo

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

ByQuantisnow·Wall Street's wire, on your screen.
VRDN· Viridian Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VRDN (Viridian Therapeutics Inc.) and more on Quantisnow.